Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Gains from Investment Securities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Gains from Investment Securities for 17 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 90.91% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 45.52% decrease, with the full-year FY2025 number at $7.3 million, down 45.52% from a year prior.
  • Gains from Investment Securities was $1.2 million for Q4 2025 at Myriad Genetics, down from $5.9 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $13.2 million in Q4 2024 to a low of -$9.0 million in Q3 2024.
  • A 5-year average of $2.2 million and a median of $400000.0 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 394.44% in 2022, then crashed 9100.0% in 2024.
  • Myriad Genetics' Gains from Investment Securities stood at -$3.6 million in 2021, then soared by 394.44% to $10.6 million in 2022, then decreased by 17.92% to $8.7 million in 2023, then surged by 51.72% to $13.2 million in 2024, then crashed by 90.91% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Gains from Investment Securities are $1.2 million (Q4 2025), $5.9 million (Q3 2025), and $700000.0 (Q2 2025).